{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T23:13:30Z","timestamp":1688166810167},"reference-count":23,"publisher":"Japanese Society of Internal Medicine","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Jpn. Soc. Intern. Med.","J. Jpn. Soc. Intern. Med"],"published-print":{"date-parts":[[2011]]},"DOI":"10.2169\/naika.100.1850","type":"journal-article","created":{"date-parts":[[2013,4,9]],"date-time":"2013-04-09T23:10:31Z","timestamp":1365549031000},"page":"1850-1874","source":"Crossref","is-referenced-by-count":1,"title":["3. Diagnosis, Laboratory Examination, and Treatment for Multiple Myeloma.","3\uff0e\u591a\u767a\u6027\u9aa8\u9ac4\u816b\u306e\u8a3a\u65ad\u3068\u6cbb\u7642"],"prefix":"10.2169","volume":"100","author":[{"given":"Akiyoshi","family":"Miwa","sequence":"first","affiliation":[{"name":"Hemato-oncology and Advanced Medicine, Department of Hematology, National Center for Global Health and Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Subramanian R, et al: Significance of bone marrow fibrosis in multiple myeloma. Pathology 39 (5): 512-515, 2007.","DOI":"10.1080\/00313020701570038"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) The Finnish Leukemia Group: Acute leukemia and other secondary neoplasms in patients treated with conventional chemotherapy for multiple myeloma: a Finnish Leukemia Group Study. Eur J Haematol 65: 123-127, 2000.","DOI":"10.1034\/j.1600-0609.2000.90218.x"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Attal M, et al: Maintenance treatment with lenalidomide after transplantation for myeloma: analysis of secondary malignancies within the IFM 2005-02 trial. Haematologica 96 (suppl n.1): S23, 2011.","DOI":"10.1182\/blood.V116.21.310.310"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Mccarthy P, et al: Phase III intergroup study of lenalidomide versus placebo maitenance therapy following single autologous stem cell transplant (ASCT) for multiple myeloma (MM): CALGB ECOG BMT-CTN 100104. Haematologica 96 (suppl n.1): S23, 2011.","DOI":"10.1200\/jco.2010.28.15_suppl.8017"},{"key":"5","unstructured":"5) Palumbo A, et al: Second malignancies in elderly myeloma patients. Haematologica 96 (suppl n.1): S24, 2011."},{"key":"6","unstructured":"6) Morgan G, et al: Retrospective analysis of the long term safety of lenalidomide (LEN) ±Dexamethasone (DEX) in relapsed\/refractory multiple myeloma (RRMM) patients: analysis of pooled data and incidence rates (IR) of second primary malignancy (SPM). Haematologica 96 (suppl n.1): S24, 2011."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Mufti GJ, et al: Coexistent myelodysplasia and plasma cell neoplasia. Br J Haematol 54 (1): 91-96, 1983.","DOI":"10.1111\/j.1365-2141.1983.tb02070.x"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Soenen V, et al: Myelodysplasia during the course of myeloma. Restriction of 17p deletion and p53 overexpression to myeloid cells. Leukemia 12 (2): 238-241, 1998.","DOI":"10.1038\/sj.leu.2400909"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Grogan TM, et al: Myelomonocytic antigen positive multiple myeloma. Blood 73 (3): 763-769, 1989.","DOI":"10.1182\/blood.V73.3.763.bloodjournal733763"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Yaccoby S, et al: Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood 109 (5): 2106-2111, 2007.","DOI":"10.1182\/blood-2006-09-047712"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Terpos E, et al: Increased bone mineral density in a subset of patients with relapsed multiple myeloma who received the combination of bortezomib, dexamethasone and zoledronic acid. Ann Oncol 21 (7): 1561-1562, 2010.","DOI":"10.1093\/annonc\/mdq259"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Oshima K, et al: Clinical and pathologic findings in 52 consecutively autopsied cases with multiple myeloma. Am J Hematol 67 (1): 1-5, 2001.","DOI":"10.1002\/ajh.1067"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Bhutani M, et al: Osteomalacia due to adult Fanconi syndrome in multiple myeloma. Leuk Lymphoma 52 (3): 536-538, 2011.","DOI":"10.3109\/10428194.2010.540459"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Coleman M, et al: BLT-D (clarithromycin<Biaxin>, low-dose thalidomide, and dexamethasone) for the treatment of myeloma and Waldenstroem macroglobulinemia. Leuk Lymphoma 43: 1777-1782, 2002.","DOI":"10.1080\/1042819021000006303"},{"key":"15","unstructured":"15) Kunzman V, et al: Stimulation of gammadelta T cells by amino-bisphosphonates and induction of antimyeloma cell activity in multiple myeloma. Blood96 (9): 384-392, 2000. Comments in: Blood 97 (9): 2917-2918,2001"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Okuno Y, et al: Expression of the erythropoietin receptor on a human myeloma cell line. Biochem Biophys Res Commun 170 (3): 1128-1134, 1990.","DOI":"10.1016\/0006-291X(90)90510-T"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Faggioli L, et al: Molecular mechanisms regulating induction of interleukin-6 gene transcription by interferon-gamma. Eur J Immunol 27 (11): 3022-3030, 1997.","DOI":"10.1002\/eji.1830271140"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Puthier D, et al: Interferon alpha extends the survival of human myeloma cells through an upregulation of the Mcl-1 anti-apoptotic molecule. Br J Haematol 112 (2): 358-363, 2001.","DOI":"10.1046\/j.1365-2141.2001.02575.x"},{"key":"19","unstructured":"19) Matsuzaki H, et al: Serum amino acid disturbance in multiple myeloma with hyperammonemia. Int J Hematol 61 (3): 131-137, 1995."},{"key":"20","unstructured":"20) Tsunoda S, et al: Coma, hyperviscosity syndrome, hyperammonemia and myelofibrosis in a patient with IgG-lambda type multiple myeloma. Rinsho Ketsueki 30 (3): 361-365, 1989."},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Lilleby K, et al: A prospective, randomised study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 37 (11): 1031-1035, 2006.","DOI":"10.1038\/sj.bmt.1705384"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Isshiki I, et al: Hypercalcemia after High-Dose Chemoradiotherapy for Refractory Multiple Myeloma; Subject Heading. Hematology 5 (4): 287-292, 2000.","DOI":"10.1080\/10245332.2000.11746519"},{"key":"23","unstructured":"23) Hagiwara S, et al: Multidisciplinary nutritional support for autologous hematopoietic stem cell transplantation: A cost-benefit analysis. Nutrition 2011 Apr 8. [Epub ahead of print]"}],"container-title":["Nihon Naika Gakkai Zasshi"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/naika\/100\/7\/100_1850\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T22:39:58Z","timestamp":1688164798000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/naika\/100\/7\/100_1850\/_article\/-char\/ja\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.2169\/naika.100.1850","relation":{},"ISSN":["0021-5384","1883-2083"],"issn-type":[{"value":"0021-5384","type":"print"},{"value":"1883-2083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011]]}}}